Avantor Past Earnings Performance
Past criteria checks 0/6
Avantor's earnings have been declining at an average annual rate of -20.9%, while the Life Sciences industry saw earnings declining at 3.8% annually. Revenues have been declining at an average rate of 2.4% per year.
Key information
-20.89%
Earnings growth rate
-23.06%
EPS growth rate
| Life Sciences Industry Growth | 21.51% |
| Revenue growth rate | -2.35% |
| Return on equity | -9.87% |
| Net Margin | -8.42% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Narrative Update • May 01
AVTR: Reset Expectations And Execution Progress May Support Future Upside
Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.Seeking Alpha • Apr 30
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking Alpha
Narrative Update • Apr 16
AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing
Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.Narrative Update • Apr 02
AVTR: Reset Expectations And Share Repurchases May Support Future Upside
The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.Narrative Update • Mar 19
AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing
Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.Narrative Update • Mar 05
AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential
Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.Analysis Article • Feb 13
The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%
Avantor, Inc. ( NYSE:AVTR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Narrative Update • Feb 04
AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations
Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.Narrative Update • Jan 21
AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility
Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.Narrative Update • Jan 07
AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential
Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.Narrative Update • Dec 14
AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves
Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.Narrative Update • Nov 28
AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead
Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.Narrative Update • Nov 14
AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025
Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.Analysis Article • Nov 01
Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...Narrative Update • Oct 31
AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery
Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.Analysis Article • Oct 28
There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise
Avantor, Inc. ( NYSE:AVTR ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...Narrative Update • Oct 16
Pharma Contracts And R&D Will Drive Growth Amid Price Pressures
Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.Analysis Article • Sep 12
We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Aug 12
Concerns Surrounding Avantor's (NYSE:AVTR) Performance
NYSE:AVTR 1 Year Share Price vs Fair Value Explore Avantor's Fair Values from the Community and select yours Avantor...Analysis Article • Jun 26
What Is Avantor, Inc.'s (NYSE:AVTR) Share Price Doing?
Avantor, Inc. ( NYSE:AVTR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...Seeking Alpha • Apr 26
Avantor: A Healthier Diagnosis As Expectations Cool
Summary Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio. The risk-reward profile has improved due to lower expectations, but the outlook remains cautious amidst continued sales declines and pending leadership changes. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Avantor: Mundane Business, Solid Cash Flow, Potential New Risks
Summary Avantor, Inc. has seen a significant decline in its stock price recently. The company did divest itself of one business this summer, paying down some debt with the proceeds. In addition, the company delivered an impressive amount of free cash flow in FY2024. Buy, Sell or Hold? An analysis around AVTR stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Avantor: Durable FCF Generator Trading For Cheap
Summary Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company’s capital structure and return value to shareholders. Potential industry inflection point creates optimal entry point with multiple expansion. Read the full article on Seeking AlphaSeeking Alpha • Oct 24
Avantor: Uninspiring, Even Amidst Some Green Shoots
Summary Avantor shares have struggled on the back of a high valuation, significant debt, and lackluster growth, despite recent improvements in organic sales and a divestment. The company operates two segments: a $4.7 billion laboratory solutions business, and a $2.2 billion bioscience production business, with the latter having higher margins. Recent financials show declining sales and earnings, amidst high valuation and a demanding valuation. A $650 million divestment aims to reduce debt, but the overall risk-reward remains unattractive given the company's past performance and high leverage. Read the full article on Seeking Alpha
New Narrative • Aug 21
New Operating Model And Bioprocessing Innovations Promise Robust Growth And Market Leadership
Implementation of a new operating model and ongoing cost transformation initiatives are streamlining execution and improving net margins through cost savings.Seeking Alpha • Aug 13
Avantor: Yet To Evidence Economic Value For Valuation Repricing, Reiterate Hold
Summary AVTR stock is up 18% post Q2 FY'24 earnings, but momentum and quality continue to diverge. The company's balance sheet is saddled with debt, whilst earnings produced on capital are flattening. Valuations are unsupportive at >35x earnings, and I continue to rate AVTR a hold with little headroom for upside under present conditions. Read the full article on Seeking AlphaRevenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Avantor makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 6,552 | -551 | 1,573 | 0 |
| 31 Dec 25 | 6,552 | -530 | 1,558 | 0 |
| 30 Sep 25 | 6,575 | -82 | 1,478 | 0 |
| 30 Jun 25 | 6,666 | 687 | 1,529 | 0 |
| 31 Mar 25 | 6,685 | 716 | 1,508 | 0 |
| 31 Dec 24 | 6,784 | 712 | 1,545 | 0 |
| 30 Sep 24 | 6,820 | 310 | 1,616 | 0 |
| 30 Jun 24 | 6,826 | 360 | 1,545 | 0 |
| 31 Mar 24 | 6,867 | 260 | 1,497 | 0 |
| 31 Dec 23 | 6,967 | 321 | 1,466 | 0 |
| 30 Sep 23 | 7,039 | 364 | 1,470 | 0 |
| 30 Jun 23 | 7,176 | 423 | 1,475 | 0 |
| 31 Mar 23 | 7,342 | 610 | 1,469 | 0 |
| 31 Dec 22 | 7,512 | 662 | 1,452 | 0 |
| 30 Sep 22 | 7,625 | 598 | 1,442 | 0 |
| 30 Jun 22 | 7,603 | 572 | 1,445 | 0 |
| 31 Mar 22 | 7,551 | 534 | 1,463 | 0 |
| 31 Dec 21 | 7,386 | 508 | 1,426 | 0 |
| 30 Sep 21 | 7,269 | 466 | 1,442 | 0 |
| 30 Jun 21 | 7,040 | 267 | 1,388 | 0 |
| 31 Mar 21 | 6,660 | 169 | 1,345 | 0 |
| 31 Dec 20 | 6,394 | 52 | 1,342 | 0 |
| 30 Sep 20 | 6,127 | 71 | 1,336 | 0 |
| 30 Jun 20 | 6,026 | 135 | 1,332 | 0 |
| 31 Mar 20 | 6,079 | -226 | 1,334 | 0 |
| 31 Dec 19 | 6,040 | -335 | 1,329 | 0 |
| 30 Sep 19 | 5,990 | -514 | 1,294 | 0 |
| 30 Jun 19 | 5,981 | -554 | 1,303 | 0 |
| 31 Mar 19 | 5,926 | -330 | 1,305 | 0 |
| 31 Dec 18 | 5,864 | -356 | 1,321 | 0 |
| 30 Sep 18 | 5,120 | -639 | 1,215 | 0 |
| 31 Dec 17 | 1,247 | -415 | 376 | 0 |
| 31 Dec 16 | 691 | -42 | 257 | 0 |
| 31 Dec 15 | 637 | 22 | 185 | 0 |
Quality Earnings: AVTR is currently unprofitable.
Growing Profit Margin: AVTR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVTR is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare AVTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVTR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (3.8%).
Return on Equity
High ROE: AVTR has a negative Return on Equity (-9.87%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 06:44 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avantor, Inc. is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |